335 related articles for article (PubMed ID: 18164818)
1. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain.
Webster L; Jansen JP; Peppin J; Lasko B; Irving G; Morlion B; Snidow J; Pierce A; Mortensen E; Kleoudis C; Carter E
Pain; 2008 Jul; 137(2):428-440. PubMed ID: 18164818
[TBL] [Abstract][Full Text] [Related]
2. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
Irving G; Pénzes J; Ramjattan B; Cousins M; Rauck R; Spierings EL; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
J Pain; 2011 Feb; 12(2):175-84. PubMed ID: 21292168
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
Jansen JP; Lorch D; Langan J; Lasko B; Hermanns K; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
J Pain; 2011 Feb; 12(2):185-93. PubMed ID: 21292169
[TBL] [Abstract][Full Text] [Related]
4. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial.
Paulson DM; Kennedy DT; Donovick RA; Carpenter RL; Cherubini M; Techner L; Du W; Ma Y; Schmidt WK; Wallin B; Jackson D
J Pain; 2005 Mar; 6(3):184-92. PubMed ID: 15772912
[TBL] [Abstract][Full Text] [Related]
5. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
[TBL] [Abstract][Full Text] [Related]
6. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.
Webster L; Dhar S; Eldon M; Masuoka L; Lappalainen J; Sostek M
Pain; 2013 Sep; 154(9):1542-1550. PubMed ID: 23726675
[TBL] [Abstract][Full Text] [Related]
7. Naloxegol for opioid-induced constipation in patients with noncancer pain.
Chey WD; Webster L; Sostek M; Lappalainen J; Barker PN; Tack J
N Engl J Med; 2014 Jun; 370(25):2387-96. PubMed ID: 24896818
[TBL] [Abstract][Full Text] [Related]
8. Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
Rauck R; Slatkin NE; Stambler N; Harper JR; Israel RJ
Pain Pract; 2017 Jul; 17(6):820-828. PubMed ID: 27860208
[TBL] [Abstract][Full Text] [Related]
9. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.
Katakami N; Oda K; Tauchi K; Nakata K; Shinozaki K; Yokota T; Suzuki Y; Narabayashi M; Boku N
J Clin Oncol; 2017 Jun; 35(17):1921-1928. PubMed ID: 28445097
[TBL] [Abstract][Full Text] [Related]
10. Alvimopan.
Neary P; Delaney CP
Expert Opin Investig Drugs; 2005 Apr; 14(4):479-88. PubMed ID: 15882122
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Alvimopan on Return of Bowel Function After Major Spine Surgery - A Prospective, Randomized, Double-Blind Study.
Dunn LK; Thiele RH; Lin MC; Nemergut EC; Durieux ME; Tsang S; Shaffrey ME; Smith JS; Shaffrey CI; Naik BI
Neurosurgery; 2019 Aug; 85(2):E233-E239. PubMed ID: 30951602
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials.
McNicol E; Boyce DB; Schumann R; Carr D
Pain Med; 2008 Sep; 9(6):634-59. PubMed ID: 18828197
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
J Clin Oncol; 2017 Dec; 35(34):3859-3866. PubMed ID: 28968171
[TBL] [Abstract][Full Text] [Related]
14. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
Webster LR; Yamada T; Arjona Ferreira JC
Pain Med; 2017 Dec; 18(12):2350-2360. PubMed ID: 28371937
[TBL] [Abstract][Full Text] [Related]
15. Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist.
Schmidt WK
Am J Surg; 2001 Nov; 182(5A Suppl):27S-38S. PubMed ID: 11755894
[TBL] [Abstract][Full Text] [Related]
16. Insights on efficacious doses of PAMORAs for patients on chronic opioid therapy or opioid-naïve patients.
van Malderen K; Halawi H; Camilleri M
Neurogastroenterol Motil; 2018 May; 30(5):e13250. PubMed ID: 29119706
[TBL] [Abstract][Full Text] [Related]
17. Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.
Holder RM; Rhee D
Pharmacotherapy; 2016 Mar; 36(3):287-99. PubMed ID: 26945548
[TBL] [Abstract][Full Text] [Related]
18. Incidence, prevalence, and management of opioid bowel dysfunction.
Pappagallo M
Am J Surg; 2001 Nov; 182(5A Suppl):11S-18S. PubMed ID: 11755892
[TBL] [Abstract][Full Text] [Related]
19. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans.
Holzer P
Neurosci Lett; 2004 May; 361(1-3):192-5. PubMed ID: 15135926
[TBL] [Abstract][Full Text] [Related]
20. New Formulation of Sustained Release Naloxone Can Reverse Opioid Induced Constipation Without Compromising the Desired Opioid Effects.
Sanders M; Jones S; Löwenstein O; Jansen JP; Miles H; Simpson K
Pain Med; 2015 Aug; 16(8):1540-50. PubMed ID: 26110375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
